The US Drug Administration has denied approval for the marketing of the drug Avastin, marketed by Roche, as a treatment for breast cancer. The product is already sold in the US for the treatment of colon cancer and in Europe it has obtained the approval of the authorities to be sold as a drug against breast cancer. The US stop caused a jolt for Roche stock, which collapsed to the lowest level in the last 12 months. After touching -5.5%, it closed the session at -3.2 per cent. This is the most dramatic collapse recorded since the company went public, after the slide on 9/11. Finance and Markets of 07/12/2007 p. 14
